A neuroimaging biomarker for disease staging in clinically diagnosed Alzheimer’s disease
Authors:
Open Access
- 5 February 2026
- journal article
- research article
- Published by Springer Nature in BMC Medicine
- Vol. 24 (1)
Abstract
Precision medicine for Alzheimer’s disease (AD) requires the development of a robust management framework grounded in individualized disease stagingKeywords
Funding Information
- BUPT Excellent Ph.D. Students Foundation (No. CX2023117)
- Natural Science Foundation of Beijing Municipality (No. 7244519)
- National Natural Science Foundation of China (No. T2425027, No.62333002)
This publication has 50 references indexed in Scilit:
- Standardized statistical framework for comparison of biomarkers: Techniques from ADNIAlzheimer's & Dementia, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Convergent Neuroimaging and Molecular Signatures in Mild Cognitive Impairment and Alzheimer’s Disease: A Data-Driven Meta-Analysis with N = 3,118Neuroscience Bulletin, 2024
- Tau accumulation and atrophy predict amyloid independent cognitive decline in agingAlzheimer's & Dementia, 2024
- HealthyGAN: Learning from Unannotated Medical Images to Detect Anomalies Associated with Human Disease2022
- Current advances in digital cognitive assessment for preclinical Alzheimer's diseaseAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2021
- Role of Anti-dementia Medication2020
- Generalizable, Reproducible, and Neuroscientifically Interpretable Imaging Biomarkers for Alzheimer's DiseaseAdvanced Science, 2020
- Staging β-Amyloid Pathology With Amyloid Positron Emission TomographyJAMA Neurology, 2019
- Cognitive Test Performance in Detecting, Staging, and Tracking Alzheimer's DiseaseArchives of Neurology, 1995